

GP 1631\$

Docket No.: PF-0027 US

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 6/2/00  
By: Debbie Ellis  
Printed: DEBBIE ELLIS



#17  
Plunkett  
6/2dw  
RECEIVED  
JUN 09 2000  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Coleman et al.

Title: NEW CHEMOKINE EXPRESSED IN PANCREAS

Serial No.: 08/390,740 ✓

Filing Date: February 17, 1995

Examiner: Marschel, A.

Group Art Unit: To Be Assigned

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

The undersigned certifies in accordance with 37 C.F.R. §1.97(e)(2) that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

In view of the status of the subject application, pursuant to 37 CFR §1.97(d), Applicants hereby request consideration of this Information Disclosure Statement with Certification Under 37 C.F.R. §1.97(e)(2).

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

06/08/2000 MMARMOL 00000047 090108 08390740

01 FC:122 59565 130.00 CH

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 C.F.R. §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Please charge Deposit Account No. **09-0108** the Petition fee of **\$130.00** under 37 C.F.R. §1.17(i). The Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-621 -7574.

Respectfully submitted,  
INCYTE PHARMACEUTICALS, INC.  
d/b/a INCYTE GENOMICS, INC.

Date: \_\_\_\_\_

6/2/00



Peng Ben Wang  
Reg. No. 41,420  
Direct Dial Telephone: (650) 621 -7574

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166